EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy strategy for cervical cancer targeting HPV E6/E7: Hopes and challenges

Henny Saraswati, Riza Arief Putranto, Mira Asmirajanti

Asia-Pacific Journal of Molecular Biology and Biotechnology · 30.06.2026 · 77

DOI: 10.35118/apjmbb.2026.034.2.07 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Molecular Biology and Biotechnology, online erschienen am 30.06.2026. Verfasst von Henny Saraswati und 2 weiteren Autor:innen. Die Arbeit nennt 84 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Persistent infection with Human Papillomavirus (HPPV) is recognized as the predominant etiological factor, primarily through the expression of the viral oncoproteins E6 and E7. These proteins disrupt key cell cycle regulatory pathways, promote uncontrolled cellular proliferation, and drive the malignant transformation. Although various therapeutic approaches, including surgery, chemotherapy, and radiotherapy, have been developed to reduce cervical cancer mortality, the limitations of conventional treatments, including toxicity, recurrence, and reduced efficacy in advanced-stage disease, underscore the urgent need for more effective and targeted strategies. In this context, the E6 and E7 oncoproteins have emerged as highly promising therapeutic targets, not only because of their indispensable roles in HPV-mediated oncogenesis but also due to their strong immunogenic properties. Consequently, substantial efforts have been directed toward developing E6/E7-based therapeutic vaccines. Multiple vaccine platforms, including DNA and protein-based vaccines, have demonstrated favorable safety profiles and the capacity to induce robust immune responses. Furthermore, preclinical and clinical studies suggest their potential to generate antitumor activity while offering prophylactic benefits in certain settings. Despite these advances, several challenges continue to limit the clinical translation and therapeutic efficacy of E6/E7-targeted vaccines. One major barrier is the tumor microenvironment (TME), which suppresses host antitumor immunity and attenuates vaccine-induced immune responses. In addition, intratumoral heterogeneity may facilitate immune escape mechanisms, allowing malignant cells to evade immune surveillance and persist, despite treatment. Therefore, future directions for E6/E7-based vaccine development should focus on overcoming these barriers through combination strategies with other immunotherapeutic modalities, particularly immune checkpoint inhibitors (ICIs), as well as the incorporation of more potent adjuvants, multi-epitope vaccine design, and precision medicine approaches. Collectively, these advances may enhance therapeutic efficacy and pave the way for more personalized and durable treatment options for patients with cervical cancer.

Zitieren

APA

Saraswati, H., Putranto, R. A., & Asmirajanti, M. (2026). Immunotherapy strategy for cervical cancer targeting HPV E6/E7: Hopes and challenges. Asia-Pacific Journal of Molecular Biology and Biotechnology, 77. https://doi.org/10.35118/apjmbb.2026.034.2.07

Vancouver

Saraswati H, Putranto RA, Asmirajanti M. Immunotherapy strategy for cervical cancer targeting HPV E6/E7: Hopes and challenges. Asia-Pacific Journal of Molecular Biology and Biotechnology. 2026:77. doi:10.35118/apjmbb.2026.034.2.07

BibTeX
@article{Saraswati2026,
  author = {Saraswati, Henny and Putranto, Riza Arief and Asmirajanti, Mira},
  title = {Immunotherapy strategy for cervical cancer targeting HPV E6/E7: Hopes and challenges},
  journal = {Asia-Pacific Journal of Molecular Biology and Biotechnology},
  year = {2026},
  pages = {77},
  doi = {10.35118/apjmbb.2026.034.2.07}
}
Kostenlos starten →